×
About 2,563 results

ALLMedicine™ Mastocytosis Center

Research & Reviews  724 results

Acute increases in total serum tryptase unassociated with hemodynamic instability in di...
https://doi.org/10.1016/j.anai.2022.04.030
Annals of Allergy, Asthma & Immunology : Official Publica... Awan SF, Schwartz LB et. al.

May 15th, 2022 - Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis.|2022|Awan SF,Schwartz LB,Maric I,Metcalfe DD,Carter MC,|

Differential mast cell mediators in Systemic Mastocytosis and Hereditary Alpha-tryptase...
https://doi.org/10.1016/j.jaci.2022.04.025
The Journal of Allergy and Clinical Immunology; Giannetti MP, Godwin G et. al.

May 14th, 2022 - Patients with systemic mastocytosis often have symptoms of mast cell activation which is associated with elevated levels of urinary mast cell mediator metabolites. Patients with hereditary alpha-tryptasemia (HαT) may present with symptoms of mast ...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 13th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Normal Blood, Bone Marrow and Buccal Mucosa Protocol
https://clinicaltrials.gov/ct2/show/NCT00806364

May 13th, 2022 - This protocol is designed to provide blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors for use in in vitro studies such as studies of cells of the immune system, mastocy...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

May 5th, 2022 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 20th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and ...
https://doi.org/10.1111/j.1365-2222.2011.03788.x
Clinical and Experimental Allergy : Journal of the Britis... Krishna MT, Ewan PW et. al.

Aug 19th, 2011 - This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

see more →

Drugs  201 results see all →

Clinicaltrials.gov  22 results

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 13th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Normal Blood, Bone Marrow and Buccal Mucosa Protocol
https://clinicaltrials.gov/ct2/show/NCT00806364

May 13th, 2022 - This protocol is designed to provide blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors for use in in vitro studies such as studies of cells of the immune system, mastocy...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

May 5th, 2022 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03580655

Mar 28th, 2022 - This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neopl...

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
https://clinicaltrials.gov/ct2/show/NCT02561988

Mar 28th, 2022 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...

see more →

News  75 results

Avapritinib Approved in Europe for Advanced Systemic Mastocytosis
https://www.onclive.com/view/avapritinib-approved-in-europe-for-advanced-systemic-mastocytosis

Mar 25th, 2022 - The European Commission has expanded the current indication for avapritinib (Ayvakyt) to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast ...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis
https://www.onclive.com/view/eu-panel-recommends-avapritinib-for-advanced-systemic-mastocytosis

Jan 31st, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended to expand the current indication for avapritinib (Ayvakyt) to include use as a single agent in the treatment of adult patients with aggressive sy...

Case: Older patient with T2D has recurrent flushing
https://www.mdedge.com/internalmedicine/article/248875/geriatrics/case-older-patient-t2d-has-recurrent-flushing
Douglas S. Paauw, MD

Nov 18th, 2021 - A 64 year-old man with type 2 diabetes complains of recurrent flushing for the past 6 months. He has had no other symptoms.

Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across Cancers
https://www.onclive.com/view/genomic-testing-cooperative-seeks-to-increase-accessibility-to-genomic-profiling-across-cancers

Nov 8th, 2021 - Genomic Testing Cooperative (GTC) is a diagnostic laboratory that utilizes a cooperative approach to partner with laboratories, hospitals, and oncology practices to improve accessibility to genomic testing for patients with cancer, said Maher Albi...

see more →